PDC platform Cybrexa Therapeutics completes US$25 million in Series B financing

On March 10, 2021, Cybrexa Therapeutics, Inc., a biotech company focused on oncology, announced the completion of a $25 million Series B funding round to develop novel therapies through its Alphalex ™ Peptide Drug Conjutate (PDC) oncology targeting platform.The financing includes Highcape Capital and new investor Elm Street Ventures.The funds raised will be used to support the advancement of Cybrexa’s lead drug candidate, CBX-12 (Alphalex ™ -Exatecan), into the clinic.The first patient dosing in a phase I clinical study is expected in the first half of 2021.

CBX-12 is a new type of treatment for solid tumors, which includes a highly effective topoisomerase I inhibitor payload, which is the same as the payload used in antibody-drug conjugates (ADC) and TRODELVY™ class. Compared with these ADCs, CBX-12 can target cancer cells without being affected by antigen overexpression, which will greatly expand the addressable patient population. The positive results from the GLP toxicology study of CBX-12 will provide guidance for the dosing regimen in the planned phase I trial.

About CBX-12

CBX-12 is a novel therapeutic approach for solid tumors that includes a highly potent topoisomerase I inhibitor payload in the same class as those used in antibody-drug conjugates (ADC) and Trodelvy ™.In contrast to these ADCs, CBX-12 is able to target cancer cells without being affected by antigen overexpression, which will greatly expand the addressable patient population.Cybrexa filed an IND application on February 19, 2021, and positive results from GLP toxicology studies of CBX-12 will guide the administration regimen for the planned phase I clinical trial of CBX-12.Collaborate with NCI to conduct preclinical safety and efficacy studies in solid oncology.The partnership will also explore its therapeutic potential in trials in multiple indications and in combination with other therapies, such as immunooncology and PARP inhibitors.

About the alphalex™ technology platform

The Cybrexa alphalex™ technology platform is composed of pHLIP® peptides, linkers and small molecule anticancer agents (payloads), which can achieve non-targeted targeting of antigens and intracellular delivery of high-efficiency anti-cancer treatments, thereby creating a radical change in the standard of care Therapies of treatment methods. pHLIP® peptides are a family of low pH insertion peptides targeting the surface of acidic cells. pHLIP® was developed by Yale University and the University of Rhode Island and is an exclusive license of pHLIP, Inc. alphalex™ represents the next generation of destructive tumor targeting.